

# ADAPTABLE Study

## Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness

Adrian Hernandez, MD, MHS, Co-Principal Investigator, Matthew Roe, MD, MHS, Co-Principal Investigator



### Key Objectives

- To compare the effectiveness and safety of two doses of aspirin (81 mg and 325 mg) in 20,000 high-risk patients with atherosclerotic cardiovascular disease (ASCVD)
  - Primary effectiveness endpoint: all causes of mortality, hospitalization for MI, or hospitalization for stroke
  - Primary safety endpoint: Hospitalization for major bleeding
- To compare the effects of aspirin in predefined key subgroups of ASCVD patients
  - Age, diabetes, sex
  - Race, P2Y12 inhibitor use
  - Chronic kidney disease
- To develop and refine the infrastructure for PCORnet to conduct multiple comparative effectiveness trials in the future

### Rationale

- Evidence does not exist on the most effective dose of aspirin for people with ASCVD
- Potential to prevent 19,000 deaths from heart attacks Or thousands of bleeds annually in the United States

### Design

- Electronic, computable phenotype to query electronic health records (EHR) to identify and screen potential participants
  - Golden tickets issued to eligible patients
- Multi-touch approach to reach eligible participants
  - Direct mail, email, EHR alerts, tablet-based recruitment, in-clinic conversations
- E-consent & e-randomization on study portal: theadaptablepatient.com
  - Process for participants without Internet access
- Endpoint Ascertainment
  - Routine queries of the PCORnet Common Data Model
  - Patient-reported data
  - Surveillance of the Centers for Medicare & Medicaid Services, private health plans
  - Death determination via Social Security Administration (Medicare beneficiaries) & National Death Index

### Who's Involved


- Researchers from 8 PCORnet CDRNs and 35 Health Systems
- Adaptors Team (8 patients representing each CDRN)
- Health eHeart Alliance PPRN support the Adaptors team

### Enrollment Status

CDRN	Site	Golden Tickets Entered	Enrolled	% Enrolled Per Golden Ticket Entered
MidSouth	Vanderbilt	542	259	48%
CAPriCORN	Northwestern	33	22	67%
REACHnet	Tulane	2	2	100%
REACHnet	Baylor Scott and White	9	7	78%
REACHnet	Ochsner	288	106	37%
GPC	Iowa	63	29	46%
PaTH	Temple	8	2	25%
PaTH	Univ. of Utah	5	2	40%
PaTH	UPMC	165	49	30%
PaTH	Penn St.	56	16	29%
OneFlorida	UF Gainesville	20	15	75%
<b>TOTAL</b>		<b>1191</b>	<b>509</b>	<b>43%</b>

\*As of 11/9/2016 with six of eight CDRNs enrolling.

### Participating CDRNs



### Patient Engagement



Adaptors Team at the ADAPTABLE Kick-off Meeting

- Involved in the prioritization of the research topic, protocol design, trial conduct, and plans for trial results dissemination
- Sit on the Steering Committee (one Adaptor from each CDRN)
- Sit on the Executive Committee (two Adaptors)
- Sit on the Data Safety & Monitoring Board (two patients with no other role in the study)
- Central to the empirical development of participant-centric consent form & comprehension assessment
- Integral to review and development of study portal, recruitment plans and materials

### FUNDING / ACKNOWLEDGEMENTS

Funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (Contract Number: ASP-1502-27079). All statements in this poster, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of PCORI, its Board of Governors or Methodology Committee

### CONTACT INFORMATION

Holly Robertson, PhD  
holly.robertson@duke.edu



Website: theaspirinstudy.org

